Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Phase 3
Completed
- Conditions
- Corticosteroid Refractory Acute Graft vs Host Disease
- Interventions
- Drug: Best Available Therapy (BAT)
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 310
- Registration Number
- NCT02913261
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT02913105
- Locations
- 🇬🇧
Novartis Investigative Site, Portsmouth, United Kingdom
An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes
Phase 3
Completed
- Conditions
- Periodic Fevers Syndrome
- Interventions
- Biological: Canakinumab (AIN457)
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 4
- Registration Number
- NCT02911857
- Locations
- 🇯🇵
Novartis Investigative Site, Kyoto-city, Kyoto, Japan
Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis
Completed
- Conditions
- RRMSMultiple Sclerosis
- Interventions
- Other: Observational
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 414
- Registration Number
- NCT02907281
- Locations
- 🇬🇧
Novartis Investigative Site, London, United Kingdom
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
Phase 3
Completed
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction
- Interventions
- Drug: LCZ696 (Sacubitril/Valsartan)Drug: Placebo of LCZ696 (Sacubitril/Valsartan)
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 621
- Registration Number
- NCT02900378
- Locations
- 🇬🇧
Novartis Investigative Site, Wellingborough, United Kingdom
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Phase 1
Completed
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 283
- Registration Number
- NCT02900664
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center SC-3, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Center, Boston, Massachusetts, United States
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 139
- Registration Number
- NCT02900651
- Locations
- 🇺🇸
Uni Of TX MD Anderson Cancer Cntr Dept of Onc, Houston, Texas, United States
🇺🇸UCSF ., San Francisco, California, United States
🇺🇸UCLA Santa Monica Hematology Oncology, Santa Monica, California, United States
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 458
- Registration Number
- NCT02896127
- Locations
- 🇬🇧
Novartis Investigative Site, Wigan, United Kingdom
Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT02892019
- Locations
- 🇹🇷
Novartis Investigative Site, Ankara, Turkey
Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma
Phase 3
Completed
- Conditions
- Mild Asthma
- Interventions
- Drug: QMF149 150/80 μgDrug: MF 200 μg
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 802
- Registration Number
- NCT02892344
- Locations
- 🇻🇳
Novartis Investigative Site, Hai Phong, Vietnam